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Systemic sclerosis (SSc) is a systemic autoimmune disease
characterized by widespread ﬁbrosis aﬀecting the skin, inter-
nal organs, and vasculature. However, there are currently
no systemic, disease-modifying therapies available for the
treatment of the overall condition, and the outcomes remain
poor. Studies into disease pathogenesis have identiﬁed
several pathways that are dysregulated in SSc, and novel
targeted therapies are currently being developed. In this
special issue, we invited authors to submit original research
articles, review articles, or case reports/case series describing
preclinical, translational, or clinical studies related to new
therapies for SSc.
A set of papers in this special issue focuses on iden-
tiﬁcation of new therapeutic targets in preclinical and
translational studies. V. J. Moulin’s paper is a review article
describing the role of apoptosis in the initiation and main-
tenance of disease in SSc, through eﬀects on the immune
system, vascular damage, and ﬁbroblast proliferation. This
report discusses potential therapies targeting apoptosis and
the Fas/FasL pathway that could be investigated in patients
with SSc. Other paper describes vascular changes in the
bleomycin-inducedmousemodelofSSc.Theauthorsdiscuss
the use of this mouse model to investigate targeting ﬁbrosis,
apoptosis, and cellular adhesion molecules for the treatment
of vascular disease in SSc. The paper by T. Radstake et
al. reviews the evidence that hypoxia contributes to the
pathogenesis of SSc, with a focus on the role of hypoxia
inducible factor (HIF)-1 alpha in the vasculopathy, immune
dysregulation, and ﬁbrosis in SSc. This paper summarizes
potential therapeutic interventions to bypass the dysfunc-
tional hypoxic pathway in SSc. The paper by R. De Vries
et al. describes an original research study evaluating the
accumulation of advanced glycation end products (AGE) in
the skin of patients with SSc compared with controls using a
technique called skin autoﬂuorescence. Although this study
did not ﬁnd a signiﬁcant diﬀerence in AGE accumulation in
SSc skin compared with control samples, use of angiotensin-
converting enzyme inhibitors and angiotensin II receptor
blockers in the SSc patients may have confounded the
results. The paper by E. G. Kroon et al. is an original
research article evaluating the expression of Types I and
III interferons (IFNs) and interferon-stimulated genes (ISG)
in peripheral blood mononuclear cells from SSc patients
compared with controls. This study conﬁrmed the increased
basal expression of Type I IFNs and the ISG 25OAS in
SSc, but found no induction of Type III IFNs. This paper
provides further evidence that targeting the IFN pathway
may be useful in the treatment of SSc. The paper by S. M.
Violette et al. reviews the preclinical data supporting the
role of the integrin αvβ6 in the activation of ﬁbrosis via
thetransforminggrowthfactor(TGF)-β pathway.Thispaper
summarizes in vivo evidence of the utility of blocking αvβ6
for the treatment of lung ﬁbrosis and provides rationale for
pursuing this therapeutic approach in patients with SSc-
associated interstitial lung disease.
Another set of articles includes reviews of novel therapies
that are currently being evaluated for the treatment of
SSc. The paper by M. Anderson et al. reviews the role of2 International Journal of Rheumatology
interleukin-6 (IL-6) in SSc, summarizing evidence of eﬀects
on B cells, inﬂammation, ﬁbrogenesis, and endothelial cell
activation. The paper reviews the rationale for ongoing
clinical trials of agents blocking IL-6 transsignaling for
the treatment of SSc. The paper by S.-N. Liossis et al.
reviews the published literature supporting the role of B
cells in SSc, summarizing data from animal models and
human studies. The authors then review the results of four
clinical trials assessing the eﬀects of B cell depletion with
rituximab therapy on skin disease and lung function in
patients with SSc. The paper by R. F. Spiera and J. Gordon
reviews the preclinical and clinical studies of tyrosine kinase
inhibitors, with a focus on experience with imatinib, in
the treatment of SSc and related ﬁbrotic conditions. The
authors conclude that interpretation of the results from the
completed proof-of-concept studies is diﬃcult due to the
small size and heterogeneity of the populations studied and
the open-label designs. The review article by K. Phillips et
al. describes published studies investigating the utility of
phosphodiesterase-5 inhibitors (PDE-5-I) in the treatment
of Raynaud’s phenomenon (RP) and/or digital ulcers (DU),
detailing results of studies using sildenaﬁl, vardenaﬁl, and
tadalaﬁl. The authors also list the ongoing clinical studies of
PDE-5-I for RP and DU. The paper by D. F. Fiorentino et al.
reviews the role of endothelin-1 in the pathogenesis of SSc-
associated vascular disease and summarizes the published
reports evaluating the use of endothelin receptor antagonists
in the treatment of RP and DU.
One of the sets in this special issue includes two
articles describing rare clinical manifestations of SSc, gastric
antral vascular ectasias and primary biliary cirrhosis, and
management strategies for these entities. The paper B.
Markewitz et al. is a case series describing the tolerability
and eﬃcacy of naltrexone for the treatment of pruritus and
gastrointestinal symptoms in three patients with SSc. The
paper by K. Nikolov and M. Baleva reviews the rationale for
usingintravenous immunoglobulins (IVIG)inthetreatment
of SSc. The authors also summarize the published case
reports and series supporting the potential eﬃcacy of IVIG
in the treatment of skin sclerosis in SSc.
In summary, this special issue provides an interest-
ing compilation of articles addressing potential emerging
therapies for the treatment of SSc, including information
gleaned from preclinical, translational, and clinical studies.
We, the guest editors, hope readers ﬁnd that the manuscripts
included herein oﬀer a comprehensive summary of the
current status of drug development and promising therapies
for SSc.
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